Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

In the United States, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is investigational.

Fintel reports that on February 28, 2025, JP Morgan downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Fulcrum Therapeutics in a report released on Wednesday, February 26th. HC Wainwright analyst A. Fein now ...

Gmail vs Outlook for business: features. Gmail and Outlook are both widely used email platforms that offer a range of ...

The USDA’s Chief Economist was one of the featured speakers during the opening ceremonies of USDA’s Ag Outlook Forum Thursday ...

There is huge unmet need for new rare disease therapies, where patients have few or no available options. According to the ...